U.S. Gene Editing Market Report 2022: Diverse Application Areas of Gene Editing Fuel Growth – ResearchAndMarkets.com

DUBLIN–()–The “U.S. Gene Editing Market – Industry Outlook and Forecast 2022-2027” report has been added to from ResearchAndMarkets.com offer.

The US gene editing market is expected to grow at a CAGR of 21.13% during the period 2022-2027.

MARKET OVERVIEW

The growth of the gene editing market is fueled by the growing demand for synthetic genes in the United States. Genomics can be used to identify genetic abnormalities in humans, drug discovery, agriculture, veterinary medicine and forensics. Gene editing requires tools and techniques that make unique changes to the DNA sequence of an organism’s genes, fundamentally changing the genetic fingerprint. Unlike genetic engineering, which randomly incorporates genetic material into the host’s genome, gene editing aims to make changes to specific target locations.

Genome editing technology is a technique of modifying the target gene that allows the inactivation and addition of specific DNA fragments. This technique is widely used in biomedical research, clinics and agriculture. A growing preference for personalized medicine, research into the treatment of rare diseases, increasing R&D spending and the growth of pharmaceutical and biotech industries, rapid advances in genome sequencing and editing technologies, and the use growing number of products derived from genetically modified organisms. These are some of the factors driving the growth of the US gene editing market.

MARKET TRENDS AND OPPORTUNITIES

The emergence of new gene editing tools

  • CRISPR is changing the way scientists work on gene editing, delivering unprecedented precision. However, CRISPR technology is uncertain and has limitations that take the leap from gene therapy and cell therapy labs to the bedside.

  • Base editing is an innovative technology that can create gene knockouts and correct specific errors and mutations in the DNA of whole cells. Single nucleotide polymorphisms are highly pathogenic mutations that cause human disease and require only a single nucleotide change to correct the mutation

Increased pharmaceutical/biotech, venture capital and government funding for gene editing projects

  • Genome editing aims to alter the DNA sequence so that cells can once again make the correct protein. The NIH created the SCGE program in January 2018 to improve genome editing technology and make genome editing therapies more widely available. Genome editing has great potential to change the treatment environment for common and rare diseases. Gene editing is in its infancy, and these newly funded projects promise better strategies to address various challenges, including the right genes in the genome. Over the past decade, the US gene editing market has seen many new investments from governments, private capital, and venture capitalists.

  • The most exciting developments in CRISPR therapies often come from start-ups. However, CRISPR treatments are also attracting interest from big pharma. Start-ups and big pharma often choose to partner. Some examples of small/large partnerships include Beam Therapeutics-Pfizer & Metagenomi-Moderna.

Diverse Application Areas of Gene Editing

  • Genome editing is widely used in the study of a wide variety of organisms. For example, CRISPR creates “knockout” models of various animal diseases, allowing researchers to investigate the underlying genetic cause. He also alters the genes of specific tissues and organs, focusing on criminal genes to aid in disease research, creating disease cell models like human pluripotent stem cells, and creating pig organs.

  • Several technologies, including zinc finger endonucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), and clustered, regularly spaced, palindrome-repeating CRISPR/CRISPR-related nuclease systems (CRISPR/Cas) are used to perform gene editing. Due to its simple design, rapid implementation, low cost, and robust scalability, researchers consider the CRISPR/Cas system to be an innovative gene-editing toolkit that extends to almost any genomic targets. This system is widely used, especially in cancer research, and is a potential approach to diagnosing and treating cancer.

SEGMENTATIONS

Segmentation by products

  • Reagents & Consumables

  • Equipment and software

  • Services

Segmentation by technology

Segmentation by application

  • Drug Discovery and Development (DDD)

  • Animal Gene Editing

  • Plant gene editing

  • Others

Segmentation by end user

  • Pharmaceutical and biotechnology companies (PBC)

  • Academic and Research Institutes (ARI)

  • Animal and Plant Biotechnology Companies (APBC)

  • CRO/CDMO

Main suppliers

  • AgilentTechnologies

  • creative biogenic

  • genscriptive

  • Merck KGaA

  • Thermo Fisher Scientific

  • Takara Organic

Other Important Suppliers

  • Arbor Biotechnology

  • Beam Therapy

  • Bluebird Organic

  • Cellectis

  • Caribou Biosciences

  • Charles River Laboratories

  • CRISPR therapeutics

  • HERA Biolabs

  • Integrated DNA technologies

  • lonza

  • New England Biolabs

  • OriGene Technologies

  • Synthego

  • Tecan

  • Perkin Elmer

  • Precision Biosciences

  • Therapeutic Intellia

  • Per pair

  • Therapeutic Sangamo

  • Recombinant

  • Synbio Technologies

Main topics covered:

1 Research methodology

2 research objectives

3 Research process

4 Scope and coverage

5 Report assumptions and caveats

6 The market at a glance

7 premium previews

8 Presentation

9 Opportunities and Market Trends

10 Market Growth Catalysts

11 Market Constraints

12 Market landscape

13 Product

14 Technology

15 Application

16 End user

17 Competitive landscape

18 key company profiles

19 other important suppliers

20 Report Summary

21 Quantitative summary

22 Appendix

Companies cited

  • AgilentTechnologies

  • creative biogenic

  • genscriptive

  • Merck KGaA

  • Thermo Fisher Scientific

  • Takara Organic

  • Arbor Biotechnology

  • Beam Therapy

  • Bluebird Organic

  • Cellectis

  • Caribou Biosciences

  • Charles River Laboratories

  • CRISPR therapeutics

  • HERA Biolabs

  • Integrated DNA technologies

  • lonza

  • New England Biolabs

  • OriGene Technologies

  • Synthego

  • Tecan

  • Perkin Elmer

  • Precision Biosciences

  • Therapeutic Intellia

  • Per pair

  • Therapeutic Sangamo

  • Recombinant

  • Synbio Technologies

For more information on this report, visit https://www.researchandmarkets.com/r/b0a57o